戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 packaged genome is the dominant mechanism of viral inactivation.
2 dines, resulting in G to A hypermutation and viral inactivation.
3 cedure was established using 75% ethanol for viral inactivation.
4 echanistic insights to 405 nm light-mediated viral inactivation.
5  escape, transmissibility, and mechanisms of viral inactivation.
6 ot be propagated in cell culture, supporting viral inactivation.
7 ependent mechanism of visible light mediated viral inactivation.
8 es (ROS) did not participate in the detected viral inactivation, a model of virus inactivation based
9 on-N95" UV-C dose and concomitant SARS-CoV-2 viral inactivation across N95 facepieces within a commer
10 ikely leveraging complementary mechanisms of viral inactivation and clearance.
11 easons for the infectivity of Gammagard, and viral inactivation and removal steps are needed to ensur
12 the impacts of zooplankton filter feeding on viral inactivation and shows the potential for viral tra
13 ods and virus particles was not required for viral inactivation and that reactive oxygen species (ROS
14 based infectivity assay was used to evaluate viral inactivation, and a quantitative PCR assay was use
15  photochromic indicator (PCI) dosimetry with viral inactivation assays to generate high-resolution ma
16 -1 KOS was determined by yield reduction and viral inactivation assays.
17 n-situ PCI dosimetry to relate UV-C dose and viral inactivation at specific on-N95 locations, establi
18                                   Incomplete viral inactivation by D. magna was observed through reco
19                 Subsequently, Apo3G triggers viral inactivation by processively deaminating C-->U, wi
20 rt the hypothesis that in vivo intracellular viral inactivation by secretory IgA during transcytosis
21 ue interaction with bacteria and ineffective viral inactivation could be attributed to their selectiv
22    The antiviral strategy of capsid-targeted viral inactivation (CTVI) was designed to disable newly
23        In one such approach, capsid-targeted viral inactivation (CTVI), nucleases fused to viral coat
24  greater viral reduction which indicate that viral inactivation data in laboratory grade water may no
25 f inactivation kinetic models was fit to the viral inactivation data.
26 ral mutations increased rates of spontaneous viral inactivation (especially D368P) suggests that HIV-
27 revealed that EPL has two unique synergistic viral inactivation functions.
28 olet (UV) irradiation-based methods used for viral inactivation have provided an important avenue tar
29  Buffer AVL and heat treatments showed total viral inactivation in 100% of samples tested.
30 eat (60 degrees C for 15 min) also showed no viral inactivation in 67% or 100% of samples, respective
31      The antiviral effect of capsid-targeted viral inactivation in our model system, using both proph
32  of blood products, vaccine development, and viral inactivation in vivo.
33   Here, we describe a nonlethal mechanism of viral inactivation in which the lytic granule component,
34 imit (~3 mJ/cm(2)/hour) would result in ~90% viral inactivation in ~8 minutes, 95% in ~11 minutes, 99
35                              Capsid-targeted viral inactivation is a novel protein-based strategy for
36 s in the environment is highly variable, but viral inactivation is usually complete within months.
37                             The mechanism of viral inactivation may be similar irrespective of the ev
38                                Intracellular viral inactivation mechanisms such as these could greatl
39                                Intracellular viral inactivation mechanisms such as these could greatl
40 itis B and human immunodeficiency virus, and viral inactivation of clotting factor concentrates, were
41 n important cellular context for genetic and viral inactivation of TP53.
42 s home after a car commute, relatively rapid viral inactivation on cotton clothing had reduced the in
43  and factor IX concentrates prepared without viral inactivation procedures showed high frequencies of
44 onal testing for infectious disease markers, viral inactivation processes, and refinement of transfus
45 f aggregation under conditions mimicking the viral inactivation step during monoclonal antibody (mAb)
46 ith blood-borne stages that are resistant to viral-inactivation steps in the manufacturing process, s
47 he inadequacy of dose-averaged assessment of viral inactivation to be overcome in these complex situa
48                                              Viral inactivation was abolished by the addition of a sy
49 ly rapid and kinetically dominant process of viral inactivation, which may partly involve endocytosis
50 t demonstration of LIC application for broad viral inactivation with high efficiency.